Healthtech spin-out launches mobility platform

A healthtech spin-out has launched a new platform designed to improve clinical trials by capturing real-world patient mobility data.

Enoda has spun out of University College Dublin and Newcastle University to support pharmaceutical, medtech and clinical research organisations with insights into how therapies affect patients’ movement in everyday life.

The start-up’s platform is designed to address a long-standing challenge in drug development, where mobility has often been difficult to measure accurately outside controlled clinical settings.

Its technology will provide high-quality data for trials involving patients with conditions such as Parkinson’s, multiple sclerosis and COPD, where mobility can be a key indicator of health and treatment impact.

Enoda has emerged from Mobilise-D, a five-year €50 million pan-European research project focused on transforming how mobility loss is measured in people with chronic conditions.

The technology was validated through studies involving around 100 participants across six cohorts and a clinical validation study with 2366 participants across four disease cohorts.

Supported by NovaUCD, Newcastle Innovations and Enterprise Ireland, Enoda is now operating as a High-Potential Start-Up and is based at Cobh Enterprise Centre in County Cork.

Michael McMahon, chief executive of Enoda, said: “The launch of Enoda as an independent spin-out from UCD and Newcastle University marks a pivotal moment for clinical research and will realise the many benefits real-world mobility data can bring to drug development.

“By transforming the groundbreaking €50 million Mobilise-D research into a fully realised, customer-ready Electronic Data Capture platform, we are giving pharma and medtech companies the tools they need to capture accurate and meaningful mobility data.

“We are incredibly grateful to NovaUCD and Newcastle Innovations for the support received and for the backing of Enterprise Ireland as an HPSU, which significantly accelerates our mission to deploy this vital technology to the global market.”

Professor Lynn Rochester, professor of human movement science at Newcastle University and a co-founder of Enoda, added: “For years, the assessment of mobility in chronic conditions was limited by subjective or insensitive clinical tests.

“Seeing the scientific breakthroughs of the Mobilise-D consortium evolve into a robust, accessible commercial platform through Enoda ensures that our research will have a direct, lasting impact on global drug development and, ultimately, patient care.”

Professor Brian Caulfield, UCD School of public health, physiotherapy and sports science and a co-founder of Enoda, added: “Translating the complex, validated data pipelines developed during the €50 million Mobilise-D project into a scalable commercial architecture was a critical hurdle in modernizing clinical trials. 

“Through Enoda, we have established a secure Electronic Data Capture platform that allows pharmaceutical and clinical research partners to integrate validated digital mobility outcomes directly into their workflows, ensuring absolute confidence in data integrity and patient monitoring.”

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.